Erasca, Inc.
Clinical trials sponsored by Erasca, Inc., explained in plain language.
-
New drug ERAS-0015 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called ERAS-0015 in people with advanced solid tumors that have certain RAS mutations and have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose, either alone or with other drugs. About…
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for Hard-to-Treat cancers: first human trial of ERAS-4001 begins
Disease control Recruiting nowThis early-stage study tests a new drug called ERAS-4001 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and tolerable when given alone or with other treatments. About 200 participants will take part to help find …
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated May 04, 2026 16:22 UTC